Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.71 | -$12.78 | -54.41% | 834.7K | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $6.00 | -$2.91 | -32.66% | 118K | $422M | $2.51$48.91 |
| PFSA | Profusa | $3.12 | -$1.25 | -28.64% | 284.4K | $378M | $2.90$957.00 |
| VHUB | VenHub Global | $3.53 | -$1.31 | -27.02% | 472.9K | $362M | $3.40$40.30 |
| MNDY | Monday.com | $76.69 | -$21.31 | -21.75% | 7.9M | $5.0B | $73.01$342.64 |
| PGY | Pagaya Technologies | $14.91 | -$3.73 | -20.01% | 673.1K | $1.5B | $8.50$44.99 |
| RDIB | Reading International | $10.79 | -$2.67 | -19.84% | 27.3K | $306M | $5.81$17.40 |
| FLYE | Fly-E Group | $2.78 | -$0.68 | -19.65% | 14.8K | $5.6M | $2.50$161.80 |
| HIMS | Hims & Hers Health | $18.61 | -$4.41 | -19.16% | 3M | $5.2B | $16.36$72.98 |
| MPAA | Motorcar Parts Of America | $10.78 | -$2.36 | -17.96% | 223.3K | $257M | $6.04$18.12 |
| CLF | Cleveland-Cliffs | $12.18 | -$2.55 | -17.31% | 1.8M | $8.4B | $5.63$16.70 |
| ONEG | OneConstruction Group | $4.18 | -$0.73 | -14.87% | 989 | $79M | $1.00$13.50 |
| MAXN | Maxeon Solar Technologies | $3.32 | -$0.57 | -14.68% | 435.2K | $66M | $2.46$6.02 |
| SXTC | China Sxt Pharmaceuticals | $2.57 | -$0.43 | -14.33% | 4.4M | $2.6M | $2.34$1,176.00 |
| IBG | Innovation Beverage Group | $4.10 | -$0.68 | -14.23% | 49.4K | $3.3M | $3.27$49.25 |
| PLTZ | Tidal Trust II - Defiance Daily Target 2x Short Pltr ETF | $32.80 | -$4.98 | -13.18% | 1.7M | - | $19.91$75.28 |
| WAT | Waters | $336.49 | -$44.80 | -11.75% | 83.3K | $23B | $275.05$414.15 |
| CBZ | CBIZ | $33.83 | -$4.44 | -11.60% | 36.6K | $2.1B | $33.80$90.13 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
